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Please find attached our manuscript titled “Distinct Functional Modes of SUMOylation for 
Retinoid X Receptor Alpha” by Wai-Ping Lee et al.  This work was the result of collaboration 
between the laboratories of Dr Paul Thompson (University of Ulster) and Dr Peter Jurutka 
(Arizona State University) and we would be delighted if you would consider this study for 
publication in Biochemical Biophysical Research Communications. 
 
The report investigates the potential for human Retinoid X Receptor (hRXR) as a substrate for 
SUMOylation and the novel factors that may modulate this process.  RXR is a pivotal member 
of the nuclear receptor superfamily and integral to the transcriptional regulation of 
embryogenesis, metabolism and homeostasis.  Understanding how post translational events such 
as SUMOylation impact upon RXR functionality will be critical for delineating how this receptor 
imparts its regulatory effects in a cell and gene-specific fashion under different physiological and 
cellular challenges.   
An earlier report by Choi et al (2006) detailed hRXR to possess a SUMO acceptor site at lysine 
108 within the AF-1 region of this receptor.  This was an elegant study that focused on 
modification with SUMO1.  In our present submission, we confirm and extend upon these 
findings to demonstrate hRXR may be modified with all three tested SUMO isoforms and 
intriguingly find this event to be apparently reversed upon binding by the receptor of its cognate 
ligand. 
Importantly, we identify lysine 245 within the omega loop region as a second acceptor site that is 
specifically modified with SUMO2 and in a PIAS4-dependent fashion.  There are also intriguing 
indications that such modifications may be at least partially be achieved in a E3-ligase 
independent fashion.  
While we confirm lysine 108 as the predominant site of SUMOylation with RXR, the 
modification of lysine 245 is of equivocal functional relevance in terms of impact upon receptor 
activity.  The complete loss of SUMOylation at both sites has striking effects upon ligand-
induced transactivation by ligand in a fashion that may be dependent on DNA binding site 
context.  
 
We acknowledge that these findings represent an initial stage of our research that will require 
further expansion.  We do believe however that our present results are novel and given the 
considerable pharmacological relevance of RXR as a therapeutic target, will be of relevance for 
those researchers with a focus on metabolic/endocrine regulation in addition to treatment of 
Alzheimer’s Disease and provide a basis for further investigation.  
 
Our sincere thanks for your consideration of this manuscript 
Dr Paul Thompson 
University of Ulster 
 
Dr Peter Jurutka 
Arizona State University 
 
S.J. Choi, S.S. Chung, E.J. Rho et al.  Negative modulation of RXRalpha transcriptional 
activity by small ubiquitin-related modifier (SUMO) modification and its reversal by 
SUMO-specific protease SUSP1, J. Biol. Chem. 281 (2006) 30669-30677. 
 
Cover Letter
 Human Retinoid X Receptor (hRXR) can be modified with all three SUMO 
isoforms. 
 SUMOylation preferentially occurs with the unliganded form of hRXR. 
 We confirm lysine 108 as the predominant SUMO acceptor site within hRXR  
 PIAS4 facilitates modification with SUMO2 at lysine 245 of hRXR. 
 Combined loss of SUMOylation at both sites highly potentiates hRXR activity. 
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Abstract. 
The present study investigated human retinoid X receptor  (hRXR) as a substrate for 
modification with small ubiquitin like modifier (SUMO) and how members of the protein 
inhibitor of activated STAT (PIAS) family may impact upon this process.  In agreement with 
a previous study, we validate Ubc9 to facilitate SUMOylation of hRXR at lysine 108 but 
note this modification to occur for all isoforms rather than specifically with SUMO1 and to 
preferentially occur with the unliganded form of hRXR SUMOylation of hRXRis 
significantly enhanced through PIAS4-mediated activity with lysine 245 identified as a 
specific SUMO2 acceptor site modified in a PIAS4-dependent fashion.  While individual 
mutations at lysine 108 or 245 modestly increase receptor activity, the combined loss of 
SUMOylation at both sites significantly potentiates the transcriptional responsiveness of 
hRXR suggesting both sites may cooperate in a DNA element-dependent context.  Our 
findings highlight that combinatorial effects of SUMOylation may regulate RXR-directed 
signalling in a gene-specific fashion.  
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Abbreviations; 
STAT  Signal Transducers and Activators of Transcription 
PIAS  Protein Inhibitor of Activated STAT 
SUMO  Small Ubiquitin-Related Modifier 
VDR  Vitamin D Receptor 
RAR  Retinoic Acid Receptor  
FXR   Farnesoid X Receptor  
LXR   Liver X Receptor  
PPAR  Peroxisome Proliferator Activated Receptor 
RXR  Retinoid X Receptor Alpha 
Ubc9  Ubiquitin-Conjugation Enzyme 9 
RING  Really Interesting Gene 
Introduction 
Retinoid X receptor (RXR) is a nuclear receptor (NR) represented by three isotypes (α, β and 
γ) for which 9-cis retinoic acid (9-cis RA), a stereoisomer of all-trans retinoic acid (ATRA), 
represents its most commonly noted ligand [1].  RXR plays a pivotal role within NR biology 
through its capacity to regulate transcription as a homodimer and also as a heteropartner for 
NRs such as the vitamin D receptor (VDR), retinoic acid receptor (RAR), peroxisome 
proliferator activated receptor (PPAR) and liver X receptor (LXR) [2].  Functional loss of the 
RXR subtype has the most profound consequences which are lethal in homozygous 
knockout mice, with a heterozygous phenotype that closely reflects the biological functions 
of RXR-containing heterodimers [3].  Given its unique position within NR biology, RXR 
represents an attractive target of pharmaceutical interest with its most noted selective agonist 
Bexarotene (trade name Targretin) currently applied in the treatment of cutaneous T-cell 
lymphoma [4], and more recently implicated as a putative therapy for Alzheimer’s disease 
[5].  A clear requirement exists for a detailed understanding of RXR function and how its 
pleiotropic effects are impacted through metabolic challenges associated with disease, drug 
treatment or altered nutrient status, which can invoke changes in NR signalling through post-
translational modifications [6].  Human RXR (hRXR is known to be phosphorylated at 
serine 260, an event that underpins resistance of Ras-transformed keratinocytes to the 
growth-regulatory effects of both ATRA and the active vitamin D metabolite 1,25(OH)2D3 
(1,25D) [7,8].  hRXRα has also been reported to be modified with SUMO1 at lysine 108 
(K108), an event which appears to diminish the transcriptional potency of RXR 
although the impact of other SUMO isoforms and RXR ligand(s) were not considered in this 
study.  Given its unique and critical role within NR-directed signalling, we further explored 
hRXR as a substrate for SUMO-modification and evaluated novel factors that may 
modulate this process.   
Materials and Methods 
Cell Culture and Ligands 
HEK293 cells were obtained from the European Collection of Cell Culture (ECACC) and 
maintained at 37ºC, 5% CO2 in presence of DMEM + 10% FBS, 2mM L-glutamine, 50 
units/ml penicillin G and 50g/ml streptomycin.  Media and supplements were purchased 
from GIBCO (Invitrogen, Carlsbad, CA) and 9-cis retinoic acid (9-cis RA) from Sigma.  
Bexarotene was synthesized as detailed by Wagner and co-workers [10].  
Plasmids 
Expression constructs encoding hRXR(pSG5hRXRand pcDNAV5-hRXR), mouse 
PIAS proteins (pcDNAV5-PIAS, pcDNAGFP-PIAS and pcDNAHA-PIAS) and the Gal4-
based hybrid expression vector (pCMVBD-RXR have been previously detailed [11].  
Plasmids expressing His-tagged SUMO isoforms have been described by Dorval and Fraser 
[12] and were a generous gift of Prof Paul Fraser, University of Toronto. The pcDNAV5-
UBC9 expression construct and its C93S mutant variant were provided by Prof Ron Hay, 
University of Dundee and used as a template to generate the vector encoding ‘untagged’ 
Ubc9 as previously detailed [13].  The firefly luciferase-based reporter construct pLUC-
RXRE contains a retinoid X receptor responsive element (RXRE) based on a naturally 
occurring double repeat responsive element from the rat cellular retinol binding protein II 
gene [14].  The sequence used was AAAATGAACTGTGACCTGTGACCTGTGACCTG-
TGAC.  One copy of this double RXRE sequence was synthesized with an additional four 
base overhang for cloning into the HindIII and BglII sites of the pLUC-MCS reporter plasmid 
(Invitrogen).  The transcriptional responses of Gal4-RXR hybrid proteins were monitored 
through the luciferase signal generated from the pFLUC reporter (Stratagene) that contains 
five copies of the Gal4 response element.  
 
Cell-based SUMOylation assays 
Modification of hRXR with SUMO was monitored through a cell-based protocol we have 
previously described [13].  Briefly, HEK293 cells were seeded in 60mm plates before 
transfection with the appropriate combination of constructs expressing hRXR (2g), 
SUMO1/2/3 (2g), Ubc9 (1g), PIAS (1g) or mutated variant and appropriate parent vector 
control.  Cells were incubated for a total of 48 hours post-transfection including a 24 hour 
period ± 9-cis RA (1M) when considering effects of ligand.  Cell lysates were processed as 
previously detailed before overnight incubation with V5 agarose beads (Abcam) followed by 
elution and subsequent analysis through western blotting.   
Western Blotting 
Protein lysates were separated on 4-12% NuPAGE Bis/Tris gels (Invitrogen), transferred onto 
Immobilon-P membranes (Millipore Corp) and then probed using the following antibodies: 
mouse monoclonal anti-V5 (Invitrogen) at a 1:5000 dilution; mouse monoclonal anti-GFP 
(Invitrogen) at a 1:1000 dilution. Target proteins were visualized using SupersignalWest 
PicoChemiluminescent solution (Thermo Scientific) and development on autoradiographic 
film.  All membranes were re-probed with a mouse monoclonal anti--actin antibody (Sigma) 
at 1:10,000 dilution. The secondary antibody was a rabbit anti-mouse IgG (whole molecule) 
peroxidase conjugate antibody (Sigma). 
Site-Directed Mutagenesis 
Synthesis of point mutations within the appropriate hRXR encoding construct was achieved 
through the Quikchange XL site-directed mutagenesis system (Agilent Technologies) using 
the following mutagenic primer pairs; 
RXRα K108R  
5’-CAGCGAGGACATCAGGCCCCCCCTGGGC-3’ 
5’-GCCCAGGGGGGGCCTGATGTCCTCGCTG-3’ 
RXRα K245R  
5’-GGCCGTGGAGCCCAGGACCGAGACCTACG-3’ 
5’-CGTAGGTCTCGGTCCTGGGCTCCACGGCC-3’. 
Transcriptional Activation Assays 
HEK293 cells were seeded unto a 24-well plate at 100,000 cells/well and maintained for a 
period of 24 hours before introduction of plasmid via calcium phosphate precipitation.  At 16 
hours post-transfection, cells were incubated in media supplemented with 1M ligand (9-cis 
RA or bexarotene) or appropriate control for a further 24 hours, before recording of 
chemiluminescent signal using the Dual-Glo Luciferase Reporter Assay System (Promega).  
Transfection data were normalized relative to the luciferase signal produced from the 
constitutively active renilla vector (pRL-TK) and expressed as the means ± SEM from 
triplicate assays.  
 
Results 
We employed cell-based assays to evaluate the potential for hRXR to be modified with 
different SUMO isoforms and how binding of its 9-cis RA cognate ligand may impact upon 
this process.  Figure 1A details that under our specified conditions hRXR can be conjugated 
with each tested SUMO isoform, with the major modified form of the receptor appearing as a 
distinct band migrating at ~90KDa (Fig. 1A, upper arrow) and the presence of 9-cis RA 
appearing to significantly diminish this process.  To confirm these bands as specific products 
of the SUMO-enzymatic pathway, comparative assays were performed employing Ubc9 or its 
C93S variant possessing a deficient E2-SUMO conjugation function.  As depicted in Figure 
1B, hRXR-SUMO2 could only be detected in the presence of the enzymatically intact Ubc9 
(middle lane).  Finally, as data detailed above were derived from transfected cell lysates 
containing both RXR and Ubc9 expressed as V5-‘tagged’ proteins, we wished to verify that 
higher migrating bands were not related to SUMO-modified forms of V5-Ubc9 that may have 
been co-precipitated in our assay system.  Figure 1C illustrates that significantly increased 
levels of hRXR-SUMO2 are detected when using a non-tagged version of Ubc9 which also 
elicited additional higher migrating bands (~110KDa/160KDa) signifying formation of 
multiple forms of hRXR-SUMO2.  Subsequent assays described in this manuscript 
incorporate the use of the non-tagged Ubc9.   
Figure 2A describes the capacity of PIAS proteins to modulate RXRα SUMOylation.  These 
experiments involved co-expression of V5-hRXRα with the indicated combination of Ubc9, 
His-SUMO and HA-PIAS1/ 2/ 3/ 4 or the PIAS4 (W356A) mutant that is defective in E3-
SUMO ligase activity.  The upper panel details the ability of PIAS1, 2, and 3 to increase the 
formation of SUMO1-hRXRα (~90KDa), however such effects are modest when compared 
to those achieved through PIAS4 for which the appearance of an additional band (~110KDa) 
suggests possible modification at more than one site.  PIAS4 also enhanced RXRα 
conjugation with SUMO2 (Fig. 2A, middle panel and Fig. 2B) and SUMO3 (Fig. 2A, lower 
panel) with no such activity exhibited by the other PIAS proteins. As expected, the PIAS4 
W356A mutant had no effect on modification with SUMO1 or SUMO2 but intriguingly 
retained a capacity to enhance formation of SUMO2-hRXR.  We probed this observation 
further, as well as the impact of PIAS4 when expressed in the absence of exogenous SUMO 
protein.  While Figure 2C confirms a conjugated hRXR to form through co-expression of 
SUMO2 and Ubc9 (lane 2), we note that even in the absence of exogenous SUMO, the 
combined activities of PIAS4 and Ubc9 generate a modified hRXRα (lane 3) that likely 
occurs with endogenous SUMO protein. The combined expressions of PIAS4, Ubc9 and 
SUMO2 (lane 4) dramatically enhanced receptor SUMOylation and invoked appearance of 
multiple SUMO-hRXRα conjugates.  In contrast, the W356A mutant exhibited no 
comparable effects when reliant upon endogenous SUMO as substrate (lane 5) but when co-
expressed in combination with SUMO2 generated a single dominant band at ~90KDa (lane 
6).  Taken in combination, these data indicate PIAS4 to enhance RXRα modification with all 
three SUMO isoforms, an event which may involve formation of poly-SUMO chains on 
RXR and/or modification at more than one acceptor site within the receptor.  For one of 
these potential sites, PIAS4 appears to facilitate generation of RXR-SUMO2 independently 
of its RING finger ligase function. 
To investigate further if hRXR may be modified at more than one site, we compared the 
SUMOylation patterns exhibited by the wild type receptor and a variant possessing a lysine 
(K) to arginine (R) substitution at amino acid 108 (K108R) previously reported to serve as a 
SUMO1 acceptor site within hRXRα [9].  The experiments detailed in Figure 3 included 
Ubc9 and PIAS4 within all tested parameters.  Figure 3A verifies modification of wild type 
hRXR with each SUMO isoform but also demonstrates hRXR K108R capable of forming 
a conjugated species with SUMO2 with Figure 3B detailing that the presence of 9-cis RA 
will again inhibit or reverse this process.  No conjugates were detected to form between the 
K108R mutant and SUMO1 or SUMO3.  These results implicate the presence within hRXR 
of at least one acceptor site additional to K108 that is specific for SUMO2.  Analysis of the 
hRXRα protein sequence reveals SUMO consensus motifs at K201 and K245 which we then 
assessed for their relevance to receptor modification through generating K to R mutations at 
each site, alone and in combination with K108R.  In Figure 3C we highlight experiments 
focusing on K245 and K108 as potential acceptor sites.  While wild type hRXRα exhibited 
the expected pattern of modification, both the K245R and K108R mutants exhibit a single 
band corresponding to SUMO2-hRXRα. Intriguingly, the double (K108R/K245R) mutant 
RXRα demonstrated a complete loss of receptor modification verifying hRXRα to have two 
acceptor sites represented by K108 and K245, with the latter apparently specific for 
modification with SUMO2.    
We next evaluated the functional relevance of these acceptor sites upon hRXR 
transactivation by its ligand using two different reporter assay systems.  In Figure 4A, 
HEK293 cells received the appropriate expression constructs for V5-RXR or mutant 
variants in combination with the pLUC-RXRE based reporter construct that contains two 
copies of a retinoid x response element (RXRE) sequence.  The data is expressed as the fold 
increase (induction) of reporter activity that resulted from treatment with the synthetic RXR 
agonist bexarotene over that observed for vehicle control.  As illustrated, all tested variants 
exhibited a fold induction of transactivation significantly higher than the wild type hRXR 
and although all mutants are statistically equivalent, a clear trend is noted in which the 
K108R/K245R variant exhibits induction levels approximately 240% greater that of the wild 
type hRXR compared to 98% and 128% for K108R and K245R, respectively.  
Consideration of such effects upon transcriptional activity should take consideration that we 
consistently note protein levels for the double mutation to be considerably lower in the 
presence of ligand when compared to the wild type hRXR, suggesting even more 
pronounced functional differences may result if normalized based on equivalency of protein.  
In Figure 4B, each hRXR was expressed as a hybrid protein fused to the gal4 DNA binding 
domain with transactivation monitored through the pFLUC reporter containing five tandem 
copies of the gal4 response element.  The data are depicted as overall reporter activity and 
reveal the K108R/K245R mutant to exhibit a level of activity in the presence of ligand that is 
approximately 907% greater than that achieved using the wild type-based construct.  In 
contrast, the individual K108R or K245R mutants do not exhibit significantly different 
activities from the intact receptor, at least in this reporter system. 
 
Discussion 
In this current study we probe hRXR as a substrate for SUMOylation and demonstrate Ubc9 
to facilitate the modification of hRXR with all three isoforms tested in our experimental 
system, an event that is apparently reversed in the presence of the 9-cis RA RXR ligand.  
Ligand binding is known to invoke co-repressor release followed by ubiquitination and 
proteasome-mediated degradation as components within the RXRα transcriptional cycle [15, 
16].  While we note hRXR protein levels to be slightly reduced within precipitates from 
ligand-treated samples compared to vehicle control counterparts, this is not sufficient to 
explain the striking loss of receptor modification in the presence of 9-cis RA.  It is possible 
that ligand-binding may elicit changes in receptor conformation that limit the accessibility of 
acceptor sites or introduce alternate modifications at the same or neighbouring residues.  Choi 
and co-workers identified the removal of SUMO1 from RXR to be mediated through 
sentrin/SUMO specific protease (SENP) activity, specifically that of SENP6, although the 
impact of ligand within this process was not defined [9].  We recently reported that ligand-
bound VDR will recruit members of the SENP family to reverse its modification with 
SUMO2 [11].  It will be interesting to probe if such a model of ligand-driven 
deSUMOylation is also a modulatory component within the RXR transcriptional response.   
The data discussed above considers hRXR SUMOylation driven through Ubc9 activity 
alone.  In this context, Choi and co-workers identified lysine 108 (K108) within the AF1 
region of RXRas a single and atypical acceptor site [9].  While Ubc9 can effectively 
mediate SUMOylation, other sites may be ‘hidden’, and require the additional presence of an 
E3-SUMO ligase for their modification [17].  As such an example, we recently reported 
PIAS4 to serve a specific SUMO ligase function for the modification of VDR with SUMO2 
[13] and in the context of hRXRwe identify PIAS4 to also robustly enhance the 
conjugation of this receptor with each co-expressed SUMO isoform and indeed increase the 
detectable levels of hRXR modifiedwith endogenous SUMO.  Any effects noted for other 
PIAS proteins are considerably weaker and limited to a modest increase in receptor 
conjugated with SUMO1.  Intriguingly, we find the PIAS4 variant deficient in E3-ligase 
activity retains a significant capacity to enhance formation of hRXR-SUMO2, albeit at a 
level that is diminished compared to that achieved with enzymatically intact PIAS4.  Similar 
observations have been reported for YY1 in which PIAS4 is proposed to facilitate 
interactions between substrate, Ubc9 and SUMO that serve to increase the accessibility of 
acceptor sites for conjugation [18].  Our results also highlight an intriguing possibility that 
hRXR may possess acceptor sites that are alternately modified through distinct PIAS4-
directed pathways which we seek to verify and further characterize.   
Our data identify K245, a residue located within the omega loop region of RXR as an 
additional SUMO acceptor site to K108.  The pattern of modification exhibited by the 
K108R-RXR mutant reveals it retains a capacity to be specifically modified with SUMO2 
in the presence of PIAS4, , an event that is again reversed through the presence of ligand. 
Taken in combination our data indicate K108 to be the predominant acceptor site within 
RXR that can be conjugated with all three SUMO isoforms, while K245 is specifically 
modified by SUMO2 in a PIAS4-dependent fashion. 
SUMO-modified nuclear receptors typically exhibit decreased levels of transactivation and 
our data also imply SUMOylation to repress the transcriptional responsiveness of RXR to 
its ligand.  Our analysis focused on hRXR signalling in a homodimeric context with 
consideration for how SUMOylation impacts upon its function as a heteropartner beyond the 
scope of this current study.  We confirm the findings of Choi and co-workers that loss of the 
K108 as an acceptor site will result in a modest but significant increase in the transcriptional 
potency of RXR but note similar effects with the K245R-RXR variant signifying that 
although this site is not as extensively modified as K108, it is of at least equal importance in 
terms of functional relevance.  The most significant changes in ligand response are displayed 
by the RXRvariant that is completely deficient in SUMOylation.  When assessed through 
the RXRE-based reporter system, the heightened levels of transactivation exhibited by the 
K108R/K245R RXR variant are an additive combination of the effects achieved by each 
individual mutation.  More striking effects are noted when activity is monitored through the 
gal4-hybrid system that utilizes a reporter construct containing five tandem copies of the 
Gal4 response element.  In this context, the levels of transactivation to ligand exhibited by the 
double mutant are profoundly increased and potentiated in a synergistic manner over those 
displayed by the intact receptor and its single mutant variants.  These data suggest that 
SUMOylation may modulate transactivation of RXR in a response element-specific fashion 
and imply that in certain promoter contexts the receptor may be subject to a functional 
interaction between its SUMO acceptor sites.   
We acknowledge that these novel albeit initial studies for how SUMOylation impacts upon 
RXR-mediated function require expansion to consider other RXR isoforms, its relevance to 
heterodimeric complexes, and effects on endogenous gene targets.  Nonetheless, our findings 
highlight possible mechanisms through which PIAS-directed activity, in response to stress or 
inflammatory stimuli, may modulate RXR transcriptional activity in a gene-selective fashion. 
Given the plethora of biological processes in which RXR participates, these are worthy of 
future analysis and a current focus of investigation within our laboratory.   
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Legends 
Figure 1  
The unliganded form of hRXR can be covalently modified with SUMO1, 2 and 3.  A. 
HEK293 cells were transfected with expression constructs for V5-hRXR and V5-Ubc9 in 
combination with His-SUMO1, His-SUMO2, His-SUMO3 or empty vector control (-) where 
indicated.   After a 24 hour period of incubation ± 9-cis RA, lysates from each treatment 
group were processed as detailed in Materials and Methods and resulting immune-
precipitated material subjected to western blot analysis using an antibody specific for the V5 
epitope tag.  The arrows highlight the detected SUMO-modified (  90KDa) and unconjugated 
(  62KDa) forms of V5-RXR.  B.  SUMOylation of hRXR is dependent upon an 
enzymatically intact Ubc9.  Cell-based assay was performed to compare the hRXR 
modification with SUMO2 when using constructs encoding V5-Ubc9 or its catalytically 
inactive C93S variant.  The lower panel confirms equal expression within precipitated lysates 
of both V5-Ubc9 forms.   C.  Detection of SUMO-hRXR is increased using the native 
(untagged) form of Ubc9.  Cell-based assays compared levels of SUMO2-hRXR detected 
using the V5-tagged (left lane) and native (right lane) forms of Ubc9.   The arrows highlight 
the V5-Ubc9 (left lane only) and hRXR detected through western blot analysis of 




PIAS4 facilitates SUMOylation of hRXR.  A. Depicted are cell-based SUMOylation assays 
in which HEK293 cells received expression constructs for His-SUMO1 (upper panel), His-
SUMO2 (middle panel) or His-SUMO3 (lower panel) each in combination with V5-hRXR 
and where indicated, Ubc9, HA-PIAS1, 2, 3, 4 or the catalytically inactive HA-PIAS4 
W356A.  Resulting immune-precipitated lysates were probed through western blot analysis 
using the V5-specific antibody.   Arrows highlight detected V5-hRXR and its slower 
migrating species conjugated with the different SUMO isoforms.   
B. Confirmation of PIAS4 as a catalyst in modification of hRXR with SUMO2.   HEK293 
cells were co-transfected with the indicated combination of plasmids encoding V5-hRXR, 
GFP-PIAS4, His-SUMO-2 and Ubc9. The upper panel denotes western blot analysis of 
immune-precipitated material processed as described above highlighting V5-hRXR and its 
SUMO-modified form.  The lower panels confirm the expression status of GFP-PIAS4, V5-
hRXR and His-SUMO2 within cell lysates derived from each treatment group using the 
appropriate antibodies specific for each epitope tag.  C.  PIAS4 can promote SUMOylation of 
hRXR independent of its E3 ligase function.  The abilities of PIAS4 and its enzymatically 
inactive W356A variant were assessed for their abilities to enhance modification of hRXR 
with SUMO2.  HEK293 cells were transfected with the indicated combinations of expression 
constructs encoding V5-hRXRα, His-SUMO2, Ubc9, HA-PIAS4 (WT) or HA-PIAS4W356A 
with (-) representing inclusion of the appropriate parent vector control.  Immune-precipitated 
lysates were subjected to the depicted western blot analysis that highlights the unconjugated 
and SUMO2-modified forms of V5-hRXR. 
 
Figure 3 
Evidence for a second SUMO acceptor site within hRXRα.  A. HEK293 cell-based 
SUMOylation assays were performed as previously described to compare modification 
profile exhibited by V5-hRXR and its K108R variant that harbours a mutation of a 
previously identified SUMO1 acceptor site.  Depicted are resulting western blot analysis 
using the V5-specific antibody of immune-precipitated cell lysates containing either wild 
type or mutant forms of V5-hRXR in combination with the indicated construct for SUMO1, 
2 , 3 or empty vector control.   B.  Confirmation that second acceptor site within RXR is 
specific for SUMO2.   HEK293 cells received expression constructs for V5-K108R RXR 
mutant and the indicated SUMO isoform and incubated ± 9-cis RA.  All treatment groups 
were processed and subjected to analysis as described above and in Materials and Methods.  
Arrows highlight both SUMO-conjugated and unmodified forms of the RXR K108R 
protein.  C.  Identification of K245 as a SUMO2 acceptor site within hRXR. Cell-based 
SUMOylation assays were performed to compare patterns of modification with SUMO2 
exhibited by wild type V5-RXR and its variants K108R, K245R and K108R/K245R.  The 
upper panel depicts western blot analysis using the anti-V5 antibody of immune-precipitated 
lysates derived from each treatment group. The lower panels confirm the expression status of 
GFP-PIAS4, V5-RXR and His-SUMO2 within lysates representing each treatment group.   
 
Figure 4.  
Loss of the K108 and K245 SUMOylation sites within hRXR increases its transactivation 
by ligand.   HEK293 cells received:  A. the pMCS-RXRE luciferase based reporter construct 
in combination with the appropriate expression constructs for V5-hRXR or its K108R, 
K245R or K108R/K245R variants; B. the pFLUC reporter vector together with pCMVBD-
based expression vector encoding RXR or the indicated mutant variants.  Treated cells were 
dosed with bexarotene (10
-6
 M) ligand or vehicle control for a period of 24 hours before 
measurement of luciferase activity.  After normalization for transfection efficiency based on 
the activity of the pRL-TK control, results were expressed as fold-inductions (ratio of activity 
in the presence:absence of ligand) for A. or relative luciferase activity for B.  All data within 
each figure represents means (± SE) of triplicate assays (n=3) where ns p ≥ 0.05, * p = 0.01-
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